Type 2 diabetes in adults: management - SGLT2 inhibitors for chronic kidney disease (update)

Consultation on draft guideline – deadline for comments 5pm on 29/09/2021 email: t2diabetesadults@nice.org.uk

Checklist for submitting comments

- Use this comments form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include document name, page number and line number of the text each comment is about.
- Combine all comments from your organisation into 1 response form. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Ensure each comment stands alone; do not cross Refer within one comment to another comment.
- Clearly mark any confidential information or other material that you do not wish to be made public. Also, ensure you state in your email to NICE that your submission includes confidential comments.
- Do not name or identify any person or include medical information about yourself or another person from which you or the person could be identified as all such data will be deleted or redacted.
- Spell out any abbreviations you use.
- For copyright reasons, do not include attachments such as research articles, letters, or leaflets. We return comments forms that have attachments without reading them. You may resubmit the form without attachments, but it must be received by the deadline.
- We have not reviewed the evidence for the recommendations shaded in grey. Therefore, please do not submit comments relating to these recommendations as we cannot accept comments on them.
- We do not accept comments submitted after the deadline stated for close of consultation.

You can see any guidance that we have produced on topics related to this guideline by checking NICE Pathways.

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.
Type 2 diabetes in adults: management - SGLT2 inhibitors for chronic kidney disease (update)

Consultation on draft guideline – deadline for comments 5pm on 29/09/2021 email: t2diabetesadults@nice.org.uk

<table>
<thead>
<tr>
<th>Organisation name (if you are responding as an individual rather than a registered stakeholder please specify).</th>
<th>Royal College of Physicians and Surgeons of Glasgow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disclosure (please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry).</td>
<td>None</td>
</tr>
<tr>
<td>Name of person completing form</td>
<td>Dr Richard Hull, Honorary Secretary with experts in the field</td>
</tr>
</tbody>
</table>

Please read the checklist above before submitting comments. We cannot accept forms that are not filled in correctly.

We would like to hear your views on the draft recommendations presented in the guideline, and any comments you may have on the rationale and impact sections in the guideline and the evidence presented in the evidence reviews documents. We would also welcome views on the Equality Impact Assessment.

In addition to your comments below on our guideline documents, we would like to hear your views on these questions. Please include your answers to these questions with your comments in the table below.

1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.
2. Would implementation of any of the draft recommendations have significant cost implications?
3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.)

See Developing NICE guidance: how to get involved for suggestions of general points to think about when commenting.

Please return to: t2diabetesadults@nice.org.uk
Consultation on draft guideline – deadline for comments 5pm on 29/09/2021 email: t2diabetesadults@nice.org.uk

<table>
<thead>
<tr>
<th>Comment number</th>
<th>Document [e.g. guideline, evidence review A, B, C etc., methods, EIA]</th>
<th>Page number ‘General’ for comments on whole document</th>
<th>Line number ‘General’ for comments on whole document</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Guideline</td>
<td>General</td>
<td>General</td>
<td>The Royal College of Physicians and Surgeons of Glasgow although based in Glasgow has a membership of 15,000 and represents Fellows and Members throughout the UK. While NICE has a remit for England, many of the recommendations are applicable to all devolved nations including Scotland. They should be considered by the relevant Ministers of the devolved governments. The College welcomes this guidance update and endorse its principles.</td>
</tr>
<tr>
<td>2</td>
<td>Guideline</td>
<td>General</td>
<td>General</td>
<td>Our Expert reviewer considered there were no issues with this guideline. There were clear and concise recommendation concerning the use of SGLT-2 inhibitors in CKD.</td>
</tr>
</tbody>
</table>

Data protection
The information you submit on this form will be retained and used by NICE and its advisers for the purpose of developing its guidance and may be passed to other approved third parties. Please do not name or identify any individual patient or refer to their medical condition in your comments as all such data will be deleted or redacted. The information may appear on the NICE website in due course in which case all personal data will be removed in accordance with NICE policies.

By submitting your data via this form you are confirming that you have read and understood this statement.

For more information about how we process your data, please see our privacy notice.